Please assess the completion status of the following clinical trial:

Trial Title: A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a clinical diagnosis of OI Type I, III or IV with a confirmed defect in the COL1A1/COL1A2 genes, as confirmed by genetic testing~* One or more fractures in the past 5 years~* Capable of giving signed consent~Exclusion Criteria:~* History of skeletal malignancies or other bone diseases (other than OI)~* History of neural foraminal stenosis (except if due to scoliosis)~* History of myocardial infarction, angina pectoris, ischaemic stroke or transient ischaemic attack~* History of endocrine or thyroid/parathyroid conditions that could affect bone metabolism~* Treatment with bisphosphonates within 3 months of randomisation~* Treatment with teraparatide, denosumab or other anabolic/anti-reabsorptive medications within 6 months of randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Setrusumab 20 mg/kg (Blinded) (Type: EXPERIMENTAL): Setrusumab 20 mg/kg intravenous (IV) infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
- Setrusumab 8 mg/kg (Blinded) (Type: EXPERIMENTAL): Setrusumab 8 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
- Setrusumab 2 mg/kg (Blinded) (Type: EXPERIMENTAL): Setrusumab 2 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
- Setrusumab 20 mg/kg (Open-Label) (Type: EXPERIMENTAL): Setrusumab 20 mg/kg IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo IV infusion once a month for 12 months plus 500 mg calcium oral tablets and 800 IU vitamin D capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).